1. Dufresne TE, Chmielewski PA, Manhart MD et al. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 2003; 73(5): 423–432.
2. Jackson RD, LaCroix AZ, Gass M et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354(7): 669–683. Erratum in N Engl J Med. 2006; 354(10): 1102.
3. Sturdee DW, Panay N. [nternational Menopause Society Writing Group]. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010; 13(6): 509–522. Dostupné z DOI: <http://dx.doi.org/10.3109/13697137.2010.522875>.
4. National Institutes of Health. State-of-the-Science Conference Statement: Management of menopause-related symptoms. Ann Intern Med 2005; 142(12 Pt 1): 1003–1013.
5. Margolis KL, Bonds DE, Rodabough RJ et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women‘s Health Initiative Hormone Trial. Diabetologia 2004; 47(7): 1175–1187.
6. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women‘s Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321–333.
7. Salpeter SR, Cheng J, Thabane L et al. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med 2009; 122(11): 1016–1022. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2009.05.021>.
8. Felson DT, Zhang Y, Hannan MT et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329(16): 1141–1146.
9. Chlebowski RT, Hendrix SL, Langer RD et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women‘s Health Initiative Randomized Trial. JAMA 2003; 289(24): 3243–3253.
10. Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J Am Coll Cardiol 2006; 47(9): 1741–1753.
11. Canonico M, Oger E, Plu-Bureau G et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115(7): 840–845.
12. Prentice RL, Manson JE, Langer RD et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009; 170(1): 12–23. Dostupné z DOI: <http://dx.doi.org/10.1093/aje/kwp115>.
13. Rey JR, Cervino EV, Rentero ML et al. Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice. Open Orthop J 2009; 3: 14–21. Dostupné z DOI: <http://dx.doi.org/10.2174/1874325000903010014>.
14. Arts J, Kuiper GG, Janssen JM et al. Differential expression of estrogen receptors alpha and beta mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology 1997; 138(11): 5067–5070.
15. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice. N Engl J Med 2003; 348(7): 618–629. Erratum in N Engl J Med 2003; 348(12): 1192.
16. Baniahmad C, Nawaz Z, Baniahmad A et al. Enhancement of human estrogen receptor activity by SPT6: a potential coactivator. Mol Endocrinol 1995; 9(1): 34–43.
17. Taranta A, Brama M, Teti A et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 2002; 30(2): 368–376.
18. Viereck V, Grundker C, Blaschke S et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab 2003; 88(9): 4206–4213.
19. Messalli EM, Mainini G, Scaffa C et al. Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. Maturitas 2007; 56(1): 38–44.
20. Compston JE. Sex steroids and bone. Physiol Rev 2001; 81(1): 419–447.
21. Prestwood KM, Gunness M, Muchmore DB et al. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000; 85(6): 2197–2202.
22. Naylor KE, Jacques RM, Peel NF et al. Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia. Osteoporos Int 2016; 27(8): 2585–2592. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–016–3573-z>.
23. Chung YE, Lee SH, Lee SY et al. Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos Int 2012; 23(4): 1235–1243. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–011–1675–1>.
24. Boivin G, Lips P, Ott SM et al. Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women. J Clin Endocrinol Metab 2003; 88(9): 4199–4205.
25. Neele SJM, Evertz R, De Valk De Roo G et al. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002; 30(4): 599–603.
26. Iwata K, Li J, Follet H et al. Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone 2006; 39(5): 1053–1058.
27. Khan A, Morrison A, Cheung A et al. Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporos Int 2016; 27(3): 853–859. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–015–3335–3>.
28. Shane E, Burr D, Abrahamsen B et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014; 29(1): 1–23. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.1998>.
29. Johnston CC Jr, Bjarnason NH, Cohen FJ et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000; 160(22): 3444–3450.
30. Jolly EE, Bjarnason NH, Neven P et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003; 10(4): 337–344.
31. Kanis JA, Johnell O, Black DM et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 2003; 33(3): 293–300.
32. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282(7): 637–645.
33. Siris ES, Harris ST, Eastell R et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005; 20(9): 1514–1524.
34. Delmas PD, Ensrud KE, Adachi JD et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87(8): 3609–3617.
35. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280(24) 2077–2082.
36. Delmas PD, Genant HK, Crans GG et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003; 33(4): 522–532.
37. Cummings SR, San Martin J, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361(8): 756–765. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0809493>. Erratum in N Engl J Med. 2009; 361(19): 1914.
38. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344(5): 333–340.
39. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356(18): 1809–1822.
40. Lin T, Yan SG, Cai XZ et al. Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials. Int J Endocrinol 2014; 2014: 796510. Dostupné z DOI: <http://dx.doi.org/10.1155/2014/796510>.
41. Foster SA, Shi N, Curkendall S et al. Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. BMC women‘s health 2013; 13: 15. Dostupné z DOI: <http://dx.doi.org/10.1186/1472–6874–13–15>.
42. Adler RA, El-Hajj Fuleihan G, Bauer DC et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 2016; 31(1): 16–35. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.2708>.
43. Mok CC, Ying KY, To CH et al. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Ann Rheum Dis 2011; 70(5): 778–784. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2010.143453>.
44. Moen MD, Keating GM. Raloxifene: a review of its use in the prevention of invasive breast cancer. Drugs 2008; 68(14): 2059–2083.
45. Lopes-Costa PV, dos Santos AR, dos Santos LG et al. Evaluation of Ki-67 and Bcl-2 antigen expression in breast carcinomas of women treated with raloxifene. Cell proliferation 2010; 43(2): 124–129. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2184.2009.00664.x>.
46. dos Santos LG, da Silva BB. The effect of raloxifene on telomerase expression in breast carcinoma samples from postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2011; 159(1): 165–167. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejogrb.2011.06.020>.
47. da Silva BB, dos Santos AR, Pires CG et al. Effect of raloxifene on vascular endothelial growth factor expression in breast carcinomas of postmenopausal women. Cell proliferation 2009; 42(4): 506–510. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2184.2009.00615.x>.
48. Todorova VK, Kaufmann Y, Luo S et al. Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake. Cancer Chemother Pharmacol 2011; 67(2): 285–291. Dostupné z DOI: <http://dx.doi.org/10.1007/s00280–010–1316-y>.
49. Cauley JA, Norton L, Lippman ME et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65(2): 125–134. Erratum in Breast Cancer Res Treat 2001; 67(2): 191.
50. Martino S, Cauley JA, Barrett Connor E et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96(23): 1751–1761.
51. Grady D, Cauley JA, Geiger MJ et al. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst 2008; 100(12): 854–861. Dostupné z DOI: <http://dx.doi.org/10.1093/jnci/djn153>.
52. Vogel VG, Costantino JP, Wickerham DL et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) 2010; 3(6): 696–706. Dostupné z DOI: <http://dx.doi.org/10.1158/1940–6207.CAPR-10–0076>.
53. FDA Approval for Raloxifene Hydrochloride. National Cancer Institute at the National Institutes of Health: 2007. Update 2013. Dostupné z WWW: https://www.cancer.gov/about-cancer/treatment/drugs/fda-raloxifene-hydrochloride.
54. Punyadeera C, Kamps R, Defrere S et al. Effects of selective oestrogen receptor modulators on proliferation in tissue cultures of pre- and postmenopausal human endometrium. J Steroid Biochem Mol Biol 2008; 112(1–3): 102–109. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jsbmb.2008.09.002>.
55. Barrett-Connor E, Grady D, Sashegyi A et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287(7): 847–857.
56. Barrett-Connor E, Mosca L, Collins P et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355(2): 125–137.
57. Usall J, Huerta-Ramos E, Iniesta R et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2011; 72(11): 1552–1557. Dostupné z DOI: <http://dx.doi.org/10.4088/JCP.10m06610>.
58. Zanchetta JR, Hakim C, Lombas C. Observational study of compliance and continuance rates of raloxifene in the prevention and treatment of osteoporosis. Curr Ther Res Clin Exp 2004; 65(6): 470–480. Dostupné z DOI: <http://dx.doi.org/10.1016/j.curtheres.2005.01.003>.
59. Lakatos P, Takacs I, Marton I et al. A Retrospective Longitudinal Database Study of Persistence and Compliance with Treatment of Osteoporosis in Hungary. Calcif Tissue Int 2016; 98(3): 215–225. Dostupné z DOI: <http://dx.doi.org/10.1007/s00223–015–0082–6>.
60. Hadji P, Papaioannou N, Gielen E et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int 2015; 26(10): 2479–2489. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–015–3164–4>.
61. Michalská D, Štěpán JJ, Basson BR et al. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2006; 91(3): 870–877.
62. Eastell R, Nickelsen T, Marin F et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 2009; 24(4): 726–736. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.081215>.
63. Vestergaard P, Schwartz K, Pinholt EM et al. Stroke in relation to use of raloxifene and other drugs against osteoporosis. Osteoporos Int 2011; 22(4): 1037–1045. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–010–1276–4>.
64. Blondon M, Wiggins KL, Van Hylckama Vlieg A et al. Smoking, postmenopausal hormone therapy and the risk of venous thrombosis: a population-based, case-control study. Br J Haematol 2013; 163(3): 418–420. Dostupné z DOI: <http://dx.doi.org/10.1111/bjh.12508>.
65. Svedbom A, Hernlund E, Ivergård M et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 2013; 8: 137. Dostupné z DOI: <http://dx.doi.org/10.1007/s11657–013–0137–0>.
66. Recker RR, Mitlak BH, Ni X et al. Long-term raloxifene for postmenopausal osteoporosis. Curr Med Res Opin 2011; 27(9): 1755–1761. Dostupné z DOI: <http://dx.doi.org/10.1185/03007995.2011.606312>.